| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 7891 | 2015 |
| Nivolumab plus ipilimumab in advanced melanoma JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ... New England Journal of Medicine 369 (2), 122-133, 2013 | 4984 | 2013 |
| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 4454 | 2014 |
| Immune-related adverse events associated with immune checkpoint blockade MA Postow, R Sidlow, MD Hellmann New England Journal of Medicine 378 (2), 158-168, 2018 | 3609 | 2018 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3536 | 2017 |
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma MA Postow, J Chesney, AC Pavlick, C Robert, K Grossmann, ... New England Journal of Medicine 372 (21), 2006-2017, 2015 | 3099 | 2015 |
| Immune checkpoint blockade in cancer therapy MA Postow, MK Callahan, JD Wolchok Journal of clinical oncology 33 (17), 1974, 2015 | 2897 | 2015 |
| Immunologic correlates of the abscopal effect in a patient with melanoma MA Postow, MK Callahan, CA Barker, Y Yamada, J Yuan, S Kitano, Z Mu, ... New England Journal of Medicine 366 (10), 925-931, 2012 | 2148 | 2012 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2087 | 2014 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1958 | 2017 |
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ... Annals of Oncology 26 (12), 2375-2391, 2015 | 1532 | 2015 |
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response AC Huang, MA Postow, RJ Orlowski, R Mick, B Bengsch, S Manne, W Xu, ... Nature 545 (7652), 60-65, 2017 | 1484 | 2017 |
| Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730, 2018 | 1170 | 2018 |
| Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at … TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ... Journal of Clinical Oncology 33 (28), 3193, 2015 | 1085 | 2015 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1056 | 2017 |
| Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 … FS Hodi, J Chesney, AC Pavlick, C Robert, KF Grossmann, DF McDermott, ... The Lancet Oncology 17 (11), 1558-1568, 2016 | 991 | 2016 |
| Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review CF Friedman, TA Proverbs-Singh, MA Postow JAMA oncology 2 (10), 1346-1353, 2016 | 806 | 2016 |
| Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab B Weide, A Martens, JC Hassel, C Berking, MA Postow, K Bisschop, ... Clinical Cancer Research 22 (22), 5487-5496, 2016 | 576 | 2016 |
| Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ... Clinical Cancer Research 22 (12), 2908-2918, 2016 | 558 | 2016 |
| Immune modulation in cancer with antibodies DB Page, MA Postow, MK Callahan, JP Allison, JD Wolchok Annual review of medicine 65, 185-202, 2014 | 557 | 2014 |
